LIVIVO - Search results -

Search results

Result 1 - 10 of total 14

Search options

Article: Subgroup analyses in Orgalutran trials.

Mannaerts, B / van Hooren, E / Boerrigter, P

2001 Volume 16, Issue 12, Page(s) 2726

MeSH term(s)	Female ; Follicle Stimulating Hormone/therapeutic use ; Gonadotropin-Releasing Hormone/antagonists & inhibitors ; Humans ; Ovulation Induction ; Pregnancy ; Randomized Controlled Trials as Topic
Chemical Substances	Gonadotropin-Releasing Hormone (33515-09-2) ; Follicle Stimulating Hormone (9002-68-0)
Language	English
Publishing date	2001-12
Publishing country	England
Document type	Comment ; Letter
ZDB-ID	632776-x
ISSN	1460-2350 ; 0268-1161 ; 1477-741X
ISSN (online)	1460-2350
ISSN	0268-1161 ; 1477-741X
DOI	10.1093/humrep/16.12.2726-a
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.B 2892: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Details ▾
- See ZB MED holdings
- Order with fees

Article: Betrouwbaarheid van orale anticonceptiva tijdens langdurig gebruik van tetracycline ter behandeling van acne.

Boerrigter, P J

Nederlands tijdschrift voor geneeskunde

1991 Volume 135, Issue 26, Page(s) 1197–1198

Title translation	Reliability of oral contraceptives during long-term administration of tetracycline for the treatment of acne.
MeSH term(s)	Acne Vulgaris/drug therapy ; Contraceptives, Oral/adverse effects ; Drug Interactions ; Female ; Humans ; Tetracycline/adverse effects ; Tetracycline/therapeutic use
Chemical Substances	Contraceptives, Oral ; Tetracycline (F8VB5M810T)
Language	Dutch
Publishing date	1991-06-29
Publishing country	Netherlands
Document type	Letter
ZDB-ID	82073-8
ISSN	1876-8784 ; 0028-2162
ISSN (online)	1876-8784
ISSN	0028-2162
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Ua VI Zs.18: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Book ; Thesis: Beziehungen zwischen Änderungen der extrazellulären K + -Konzentration, des extrazellulären Volumens und des DC-Potentials in der Hirnrinde der Ratte

Boerrigter, Paul

1987

Author's details	von Paul Boerrigter
Language	German
Size	Getr. Zählung, graph. Darst, 21 cm
Document type	Book ; Thesis
Thesis / German Habilitation thesis	Univ., Diss.--Essen, 1987
Database	Former special subject collection: coastal and deep sea fishing

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Details ▾

Book ; Thesis: Beziehungen zwischen Änderungen der extrazellulären K + -Konzentration, des extrazellulären Volumens und des DC-Potentials in der Hirnrinde der Ratte

Boerrigter, Paul

1987

Author's details	von Paul Boerrigter
Language	German
Size	Getr. Zählung, graph. Darst, 21 cm
Document type	Book ; Thesis
Thesis / German Habilitation thesis	Univ., Diss.--Essen, 1987
Database	Library catalogue of the German National Library of Science and Technology (TIB), Hannover

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Details ▾

Article: International clinical experience with a new low-dose, monophasic oral contraceptive containing levonorgestrel 100 microg and ethinyl estradiol 20 microg.

Boerrigter, P J / Ellman, H / Dolker, M

Clinical therapeutics

1999 Volume 21, Issue 1, Page(s) 118–127

Abstract: Manufacturers have steadily been decreasing the amounts of estrogen and progestin in oral contraceptives (OCs) in an effort to enhance safety and tolerability while preserving contraceptive efficacy. A new formulation containing 20 microg ethinyl ... ...

Abstract	Manufacturers have steadily been decreasing the amounts of estrogen and progestin in oral contraceptives (OCs) in an effort to enhance safety and tolerability while preserving contraceptive efficacy. A new formulation containing 20 microg ethinyl estradiol (EE) and 100 microg levonorgestrel (LNG)--representing the lowest available contraceptive dose of each hormone--has undergone extensive clinical testing in the United States and Germany. A total of 1590 women in 61 centers received 20 microg EE and 100 microg LNG for 6 cycles. Overall, 4 pregnancies possibly related to treatment failure were reported, reflecting an overall Pearl Index (number of pregnancies per 100 woman-years of treatment) of 0.65 and a failure rate of 0.34%. Cycle control was typical of low-dose OC use. Spotting and breakthrough bleeding occurred most commonly during the earlier cycles in each study. Adverse events were typical of those seen with OC use and led to study discontinuation in 6.6% of the women. Intermenstrual bleeding was the cause for early study withdrawal in 2.6% of women. The study results suggest that the combination of 20 microg EE and 100 microg LNG offers the benefits of low hormone content with good contraceptive efficacy, cycle control, and tolerability.
MeSH term(s)	Adult ; Clinical Trials as Topic ; Contraceptives, Oral, Synthetic/administration & dosage ; Drug Administration Schedule ; Drug Combinations ; Estradiol Congeners/administration & dosage ; Ethinyl Estradiol/administration & dosage ; Female ; Humans ; Levonorgestrel/administration & dosage ; Menstrual Cycle ; Progesterone Congeners/administration & dosage
Chemical Substances	Contraceptives, Oral, Synthetic ; Drug Combinations ; Estradiol Congeners ; Progesterone Congeners ; Ethinyl Estradiol (423D2T571U) ; Levonorgestrel (5W7SIA7YZW)
Language	English
Publishing date	1999-01
Publishing country	United States
Document type	Journal Article ; Research Support, Non-U.S. Gov't
ZDB-ID	603113-4
ISSN	1879-114X ; 0149-2918
ISSN (online)	1879-114X
ISSN	0149-2918
DOI	10.1016/s0149-2918(00)88272-7
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 1435: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (1.OG) ab Jg. 2022: Lesesaal (EG)
Zs.MO 404: Show issues

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Book ; Online: Ecosysteemdiensten in de westelijke veenweiden

Smit, A. / Vogelzang, T.A. / Lenssinck, F.A.J. / Westerhof, R. / Oude Boerrigter, P. / Jansen, E. / Jansen, P.C. / Hack-ten Broeke, M.J.D. / de Blaeij, A.T.

2012

Abstract: Aan de hand van de Triple-O benadering, die een goede en duurzame benutting van ecosysteemdiensten als startpunt voor gebiedsontwikkeling neemt, is het gebied onder de loep genomen. Doel was het aanreiken van nieuwe ideëen en concepten voor de inrichting ...

Abstract	Aan de hand van de Triple-O benadering, die een goede en duurzame benutting van ecosysteemdiensten als startpunt voor gebiedsontwikkeling neemt, is het gebied onder de loep genomen. Doel was het aanreiken van nieuwe ideëen en concepten voor de inrichting van het westelijke veenweidegebied en het testen van de benadering. Hierbij zijn de stappen Ontdekken, Overeenkomen en Ontwikkelen gevolgd. De ervaringen met het toepassen van de Triple-O benadering zijn over het algemeen positief. Het heeft geleid tot andere ideëen en nieuwe inzichten, vooral bij de uitwerkingen van de twee business cases 'Waterboeren' en 'Rietteelt'. Het ruimtelijk verbinden van de diensten die het gebied kan leveren en de benutting ervan was ingewikkelder dan gedacht. Dit had veel te maken met het feit dat de schaal waarop ecosysteemdiensten worden geleverd per dienst verschilt en vaak anders is dan het schaalniveau waarop deze worden benut. De ecosysteemdienstenbenadering binnen het Triple-O concept lijkt zeker toepasbaar om beslissers bewust te maken van de potenties van het gebied en te helpen onderzoeken in hoeverre die potentie wordt benut. Het opschalen van de resultaten naar andere kansrijke gebieden lijkt niet zinvol. De ervaring is dat er juist zoveel meerwaarde te halen valt uit de lokale situatie en de verwachting is dat uitwerking van bedrijfssystemen met rietteelt of met water juist erg afhankelijk is van de lokale actoren (ondernemers, overheden). De uitwerkingen zijn daarom niet zo gemakkelijk naar elders de kopieren, de toepassing van de Triple-O benadering wel.
Keywords	area development ; canes and rattans ; ecosystem services ; groene hart ; integrated spatial planning policy ; noord-holland ; peat grasslands ; peatlands ; phragmites ; utrecht ; zuid-holland ; ecosysteemdiensten ; gebiedsgericht beleid ; gebiedsontwikkeling ; riet en rotan ; veengebieden ; veenweiden
Language	Dutch
Publisher	Alterra
Publishing country	nl
Document type	Book ; Online
Database	BASE - Bielefeld Academic Search Engine (life sciences selection)

Full text online

Full text

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article ; Online: A phase II dose-ranging study of mirabegron in patients with overactive bladder.

Chapple, Christopher R / Dvorak, Vladimir / Radziszewski, Pjotr / Van Kerrebroeck, Philip / Wyndaele, Jean Jacques / Bosman, Brigitte / Boerrigter, Peter / Drogendijk, Ted / Ridder, Arwin / Van Der Putten-Slob, Ingrid / Yamaguchi, Osamu

International urogynecology journal

2013 Volume 24, Issue 9, Page(s) 1447–1458

Abstract: Introduction and hypothesis: Mirabegron is a potent and selective β3-adrenoceptor agonist that may represent an alternative treatment option in place of antimuscarinics for patients with overactive bladder.: Methods: Patients completed a single- ... ...

Abstract	Introduction and hypothesis: Mirabegron is a potent and selective β3-adrenoceptor agonist that may represent an alternative treatment option in place of antimuscarinics for patients with overactive bladder. Methods: Patients completed a single-blinded, 2-week placebo run-in period followed by 12 weeks of randomized (n = 928) double-blinded treatment with mirabegron oral controlled absorption system (OCAS) 25, 50, 100, or 200 mg once-daily (QD), placebo or tolterodine extended release (ER) 4 mg QD. The primary endpoint was change from baseline to end-of-treatment in mean number of micturition episodes/24 h. Secondary endpoints included changes in mean volume voided per micturition; mean number of urinary incontinence, urgency urinary incontinence, and urgency episodes/24 h; severity of urgency; nocturia; and quality of life measures. Safety parameters included vital signs, adverse events, laboratory tests, electrocardiogram measurements and post-void residual volume. Results: Mirabegron 25, 50, 100, and 200 mg resulted in dose-dependent reductions (improvements) from baseline to end-of-treatment in micturition frequency of 1.9, 2.1, 2.1, and 2.2 micturitions/24 h respectively, versus 1.4 micturitions/24 h with placebo (p ≤ 0.05 for the mirabegron 50-, 100-, and 200-mg comparisons). There was a statistically significant improvement with mirabegron compared with placebo for most secondary endpoints including quality of life variables. While there was a significant (p < 0.05) increase from baseline in pulse rate in the mirabegron 100-mg and 200-mg groups, this was not associated with an increased incidence of cardiovascular adverse events. Conclusions: The favorable efficacy and tolerability of mirabegron in this phase II dose-finding study has led to its successful advancement into a phase III clinical development program.
MeSH term(s)	Acetanilides/adverse effects ; Acetanilides/therapeutic use ; Adrenergic beta-3 Receptor Agonists/adverse effects ; Adrenergic beta-3 Receptor Agonists/therapeutic use ; Aged ; Dose-Response Relationship, Drug ; Double-Blind Method ; Female ; Humans ; Incidence ; Internationality ; Male ; Middle Aged ; Quality of Life ; Single-Blind Method ; Thiazoles/adverse effects ; Thiazoles/therapeutic use ; Treatment Outcome ; Urinary Bladder, Overactive/drug therapy ; Urinary Incontinence/epidemiology
Chemical Substances	Acetanilides ; Adrenergic beta-3 Receptor Agonists ; Thiazoles ; mirabegron (MVR3JL3B2V)
Language	English
Publishing date	2013-03-08
Publishing country	England
Document type	Clinical Trial, Phase II ; Journal Article ; Multicenter Study ; Randomized Controlled Trial ; Research Support, Non-U.S. Gov't
ZDB-ID	1050631-7
ISSN	1433-3023 ; 0937-3462
ISSN (online)	1433-3023
ISSN	0937-3462
DOI	10.1007/s00192-013-2042-x
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 3070: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article ; Online: Efficacy and tolerability of mirabegron, a β(3)-adrenoceptor agonist, in patients with overactive bladder: results from a randomised European-Australian phase 3 trial.

Khullar, Vik / Amarenco, Gerard / Angulo, Javier C / Cambronero, Javier / Høye, Kjetil / Milsom, Ian / Radziszewski, Piotr / Rechberger, Tomasz / Boerrigter, Peter / Drogendijk, Ted / Wooning, Marianne / Chapple, Christopher

European urology

2013 Volume 63, Issue 2, Page(s) 283–295

Abstract: Background: Mirabegron, a β(3)-adrenoceptor agonist, has been developed for the treatment of overactive bladder (OAB).: Objective: To assess the efficacy and tolerability of mirabegron versus placebo.: Design, setting, and participants: ... ...

Abstract	Background: Mirabegron, a β(3)-adrenoceptor agonist, has been developed for the treatment of overactive bladder (OAB). Objective: To assess the efficacy and tolerability of mirabegron versus placebo. Design, setting, and participants: Multicenter randomised double-blind, parallel-group placebo- and tolterodine-controlled phase 3 trial conducted in 27 countries in Europe and Australia in patients ≥ 18 yr of age with symptoms of OAB for ≥ 3 mo. Intervention: After a 2-wk single-blind placebo run-in period, patients were randomised to receive placebo, mirabegron 50mg, mirabegron 100mg, or tolterodine extended release 4 mg orally once daily for 12 wk. Outcome measurements and statistical analysis: Patients completed a micturition diary and quality-of-life (QoL) assessments. Co-primary efficacy end points were change from baseline to final visit in the mean number of incontinence episodes and micturitions per 24h. The primary comparison was between mirabegron and placebo with a secondary comparison between tolterodine and placebo. Safety parameters included adverse events (AEs), laboratory assessments, vital signs, electrocardiograms, and postvoid residual volume. Results and limitations: A total of 1978 patients were randomised and received the study drug. Mirabegron 50-mg and 100-mg groups demonstrated statistically significant improvements (adjusted mean change from baseline [95% confidence intervals]) at the final visit in the number of incontinence episodes per 24h (-1.57 [-1.79 to -1.35] and -1.46 [-1.68 to -1.23], respectively, vs placebo -1.17 [-1.39 to -0.95]) and number of micturitions per 24h (-1.93 [-2.15 to -1.72] and -1.77 [-1.99 to -1.56], respectively, vs placebo -1.34 [-1.55 to -1.12]; p<0.05 for all comparisons). Statistically significant improvements were also observed in other key efficacy end points and QoL outcomes. The incidence of treatment-emergent AEs was similar across treatment groups. The main limitation of this study was the short (12-wk) duration of treatment. Conclusions: Mirabegron represents a new class of treatment for OAB with proven efficacy and good tolerability. TRIAL IDENTIFICATION: This study is registered at ClinicalTrials.gov, identifier NCT00689104.
MeSH term(s)	Acetanilides/therapeutic use ; Adrenergic beta-3 Receptor Agonists/therapeutic use ; Aged ; Australia ; Benzhydryl Compounds/therapeutic use ; Cresols/therapeutic use ; Delayed-Action Preparations/therapeutic use ; Double-Blind Method ; Europe ; Female ; Humans ; Male ; Middle Aged ; Muscarinic Antagonists/therapeutic use ; Phenylpropanolamine/therapeutic use ; Quality of Life ; Single-Blind Method ; Surveys and Questionnaires ; Thiazoles/therapeutic use ; Tolterodine Tartrate ; Treatment Outcome ; Urinary Bladder, Overactive/complications ; Urinary Bladder, Overactive/drug therapy ; Urinary Incontinence, Urge/drug therapy ; Urinary Incontinence, Urge/etiology ; Urination/drug effects
Chemical Substances	Acetanilides ; Adrenergic beta-3 Receptor Agonists ; Benzhydryl Compounds ; Cresols ; Delayed-Action Preparations ; Muscarinic Antagonists ; Thiazoles ; Phenylpropanolamine (33RU150WUN) ; Tolterodine Tartrate (5T619TQR3R) ; mirabegron (MVR3JL3B2V)
Language	English
Publishing date	2013-02
Publishing country	Switzerland
Document type	Clinical Trial, Phase III ; Comparative Study ; Journal Article ; Multicenter Study ; Randomized Controlled Trial
ZDB-ID	193790-x
ISSN	1873-7560 ; 1421-993X ; 0302-2838
ISSN (online)	1873-7560 ; 1421-993X
ISSN	0302-2838
DOI	10.1016/j.eururo.2012.10.016
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 1247: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (1.OG) ab Jg. 2022: Lesesaal (EG)
Zs.MO 294: Show issues

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article: Influence of two hormone replacement therapy regimens, oral oestradiol valerate and cyproterone acetate versus transdermal oestradiol and oral dydrogesterone, on lipid metabolism.

Schram, J H / Boerrigter, P J / The, T Y

Maturitas

1995 Volume 22, Issue 2, Page(s) 121–130

Abstract: Objective: To compare the influence on lipid metabolism of two discontinuous, sequentially combined hormone replacement therapy (HRT) regimens.: Study design: In an open, randomized study in 60 women, a full lipid profile including Lp(a) and liver ... ...

Abstract	Objective: To compare the influence on lipid metabolism of two discontinuous, sequentially combined hormone replacement therapy (HRT) regimens. Study design: In an open, randomized study in 60 women, a full lipid profile including Lp(a) and liver function tests were assessed in a fasting state at the end of treatment cycles 6 and 12. Group A was treated with 2 mg oestradiol valerate (days 1-21) sequentially combined with 1 mg cyproterone acetate (days 12-21); group B was treated with a patch releasing 50 micrograms oestradiol daily, twice a week (3 weeks), sequentially combined with 20 mg dydrogesterone (days 12-21) orally. Statistical analysis by two-sided one-way analysis of covariance (covariable is baseline) for adjusted means of lipid parameters and rank transformation analysis for lipoprotein(a) (Lp(a)) was performed. Results: Both groups were statistically comparable. The trial was completed by 45 subjects. Protocol violations occurred in 3 cases. Twelve subjects, equally divided between the groups, dropped out mainly because of adverse reactions. Both treatments were equally effective in the treatment of climacteric complaints. Liver function tests during the treatment period were normal in both groups. In group A, a statistically significant (P < 0.05) decrease versus baseline was observed in the serum levels (adjusted means) of the following parameters after 6 and 12 treatment cycles: total cholesterol (TC)-5% and -7%, respectively; low-density lipoprotein cholesterol (LDL-C) -13% and -14%, respectively; low-density lipoprotein cholesterol/high-density lipoprotein cholesterol ratio (LDL-C/HDL-C ratio) -16% and -18%, respectively. Triglycerides (TG) levels were significantly increased by 28% and nearly significantly (P = 0.07) by 25% after 6 and 12 treatment cycles, respectively. In group B, all lipid parameters (with the exception of apolipoprotein A-II which was significantly decreased after 12 treatment cycles) remained unchanged during therapy. Statistically significant differences for all aforementioned variables were found between the groups after 6 and 12 treatment cycles, respectively, with the exception of TC after 12 treatment cycles. After 6 treatment cycles, Lp(a) was decreased significantly (-18%) in group A as compared with baseline; after 12 months the decrease was -17% without reaching statistical significance. In group B, Lp(a) showed a slight but not statistically significant tendency to increase by 2% and 12% after 6 and 12 treatment cycles, respectively. Differences between both groups did not reach the level of significance. Conclusion: In this randomized, comparative study, a sequentially combined oral HRT regimen consisting of oestradiol valerate (2 mg daily on days 1-21) and cyproterone acetate (1 mg daily on days 12-21), induced a lipid pattern and probably also a change in Lp(a) levels, which is generally viewed to be more beneficial with regard to the prevention of cardiovascular disease than the lipid pattern induced by a sequentially combined regimen of transdermal 17 beta-oestradiol (50 micrograms twice weekly during three weeks) and oral dydrogesterone (20 mg daily on days 12-21).
MeSH term(s)	Administration, Cutaneous ; Administration, Oral ; Climacteric/blood ; Climacteric/drug effects ; Coronary Disease/blood ; Coronary Disease/prevention & control ; Cyproterone Acetate/administration & dosage ; Cyproterone Acetate/adverse effects ; Dose-Response Relationship, Drug ; Drug Administration Schedule ; Drug Therapy, Combination ; Dydrogesterone/administration & dosage ; Dydrogesterone/adverse effects ; Estradiol/administration & dosage ; Estradiol/adverse effects ; Estradiol/analogs & derivatives ; Estrogen Replacement Therapy ; Estrogens, Conjugated (USP)/administration & dosage ; Estrogens, Conjugated (USP)/adverse effects ; Female ; Humans ; Lipids/blood ; Lipoprotein(a)/blood ; Liver Function Tests ; Middle Aged
Chemical Substances	Estrogens, Conjugated (USP) ; Lipids ; Lipoprotein(a) ; Cyproterone Acetate (4KM2BN5JHF) ; Estradiol (4TI98Z838E) ; Dydrogesterone (90I02KLE8K)
Language	English
Publishing date	1995-09
Publishing country	Ireland
Document type	Clinical Trial ; Comparative Study ; Journal Article ; Randomized Controlled Trial ; Research Support, Non-U.S. Gov't
ZDB-ID	80460-5
ISSN	1873-4111 ; 0378-5122
ISSN (online)	1873-4111
ISSN	0378-5122
DOI	10.1016/0378-5122(95)00920-g
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 1432: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (1.OG) ab Jg. 2022: Lesesaal (EG)
Zs.MO 575: Show issues

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article: Placenta-insufficiëntie; een Scylla-Charybdissituatie

Boerrigter, P J / Kleinhout, J

Nederlands tijdschrift voor geneeskunde

1977 Volume 121, Issue 6, Page(s) 210–215

Title translation	Placental insufficiency; a Scylla and Charybdis situation.
MeSH term(s)	Abortion, Spontaneous/etiology ; Adult ; Cesarean Section ; Female ; Fetal Death/prevention & control ; Fetal Diseases/etiology ; Growth Disorders/etiology ; Humans ; Infant, Newborn ; Infant, Premature ; Placenta Diseases/complications ; Placental Insufficiency/complications ; Pregnancy ; Pregnancy Trimester, Third
Language	Dutch
Publishing date	1977-02-05
Publishing country	Netherlands
Document type	Case Reports ; Journal Article
ZDB-ID	82073-8
ISSN	1876-8784 ; 0028-2162
ISSN (online)	1876-8784
ISSN	0028-2162
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Ua VI Zs.18: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

To top

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Inter-library loan at ZB MED

More links

Kategorien

Inter-library loan at ZB MED

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

Inter-library loan at ZB MED

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito